On 26 June 2018 the Patented Medicine Prices Review Board announced the publication of the second annual edition of Meds Entry Watch 2016.
The report provides a review of long-term trends in new active substances approved by the US Food and Drug Administration, the European Medicines Agency and Health Canada between 2009 and 2015. It also:
- describes, among other things, the availability, pricing and sales of such new active substances in 2015 and 2016; and
- provides a preliminary analysis of their effect on the market as of the fourth quarter of 2016.
For further information on this topic please contact Andrew Mandlsohn at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email ([email protected]). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
This article was first published by the International Law Office, a premium online legal update service for major companies and law firms worldwide. Register for a free subscription.
